More Evidence that Women Face Greater CVD Risk than Men, Even When Baseline Health is Equal
For the same level of baseline health, the increase in risk related to each of 8 key CV risk factors appears significantly higher in women than in men.
Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose
Your daily dose of the clinical news you may have missed.
Initial Treatment with Dual Statin + Ezetimibe Cuts All-Cause Mortality by 50%: New Meta-Analysis
The reductions observed in all-cause mortality (49%) and MACE (39%) in high-risk patients compared with statin monotherapy could be practice changing, researchers said.
Marijuana Use Tied to Increased Risk for Myocardial Infarction in People Aged 50 Years and Younger
Cannabis users had a more than sixfold increased risk of MI compared to non-users, according to a new study.
Does Skin Tone Affect Efficacy of Therapy for Atopic Dermatitis? Probably Not
AAD 2025: Raj Chovatiya, MD, PhD, MSCI, well-known physician scientist, says underrepresentation in clinical trials of those with skin of color precludes an evidence-based answer.
Early Amyloid Plaque Removal May Delay Alzheimer Disease Onset, A First-of-Its-Kind Study Suggests
In a small study of adults genetically predisposed to early-onset dementia, anti-amyloid treatment to remove plaque reduced risk of developing symptoms by 50%.
Study: 72% of Asymptomatic UTI Patients Receive Unnecessary Antibiotics
Researchers recommend expanding antimicrobial stewardship efforts to better track and reduce unnecessary antibiotic use.
The 10 States with the Highest Risk for Cancer
The greatest risk for developing cancer faces residents of South Dakota, where radon levels are the nation's highest, and ranks for alcohol consumption and obesity are poor.
Guselkumab (Tremfya) Wins Approval for Crohn Disease, Fourth Indication for Immune-Mediated Diseases
The IL-23 inhibitor is the only drug in the class available with both subcutaneous and intravenous administration options for treatment induction, according to J&J.
Investigational Keto Diet Pill Shows Promise in Phase 1 Trial: Daily Dose
The Exposome is Everything in Atopic Dermatitis: An Expert Perspective on AD Pathophysiology
Raj Chovatiya, MD, PhD, MSCI, discusses the complex and widely variable influences that affect the manifestations and burden of atopic dermatitis across populations.
Universal ED Syphilis Screening Outperforms Targeted Approaches, Study Shows
CROI 2025: Researchers reported that a universal syphilis screening program identified more cases than programs targeting specific patient populations.
AGA: AI-Assisted Colonoscopy Increases Adenoma Detection, But Long-Term Benefits Unclear
New AGA guidelines conclude that it is not clear whether computer-aided detection systems for colonoscopy should be recommended for routine widespread use.
Melanin Isn't Everything: Skin Physiology Does Not Conform to Socially Defined Variables, Explains Raj Chovatiya, MD, PhD, MSCI
AAD 2025: Chovatiya discusses whether melanin concentration plays a role in skin physiology and cautioned against typing with factors that are not true biologic constructs.
Dupilumab Found Beneficial in COPD with Type 2 Inflammation: Daily Dose
Improved HPV Vaccination Coverage May Help Prevent Noncervical Cancers in People with HIV
CROI 2025: Increased HPV vaccine coverage could reduce HIV cases by thousands, according to a new study.
US Adult Vaccination Snapshots: Current Coverage, Trends, and Concerns
Get the latest immunization updates, data on racial disparities, and practical guidance for clinical practice, here.
Massive Trump Administration Cuts to Federal Grants Halt National Diabetes Prevention Program
The 30-year program has tracked and compiled data on diabetes prevention, treatment, and outcomes, providing a foundation and insights for international research.
ZUPREME-1 Phase 2b Trial of Petrelentide for Obesity Completes Enrollment
The amylin analog at 5 doses will be compared with placebo when added to a reduced calorie diet and increased physical activity regimen for 42 weeks, said Zealand Pharma.
Roflumilast Cream Shows Strong Tolerability in Patients with AD Failing Other Topicals: Daily Dose
